A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

• Status: Recruiting
• Trial end date: 2021-12-01

Summary

The purpose of this study is to test any good and bad effects of the study drug, CPI-613.

• Phase: Phase 2

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: City of Hope Medical Center; Dana-Farber Cancer Institute; George Washington University; M.D. Anderson Cancer Center; Massachusetts General Hospital